ValuEngine cut shares of Amneal Pharmaceuticals (NYSE:AMRX) from a sell rating to a strong sell rating in a report issued on Friday morning, ValuEngine reports.

Several other equities research analysts have also commented on AMRX. Royal Bank of Canada restated a hold rating and set a $4.00 target price on shares of Amneal Pharmaceuticals in a research report on Thursday, April 16th. Morgan Stanley cut their target price on Amneal Pharmaceuticals from $5.00 to $3.00 and set an equal weight rating on the stock in a research report on Thursday, April 2nd. SVB Leerink increased their price target on Amneal Pharmaceuticals from $3.00 to $4.00 and gave the stock a market perform rating in a report on Tuesday, May 12th. SunTrust Banks increased their price target on Amneal Pharmaceuticals from $4.00 to $5.00 and gave the stock a buy rating in a report on Wednesday, May 13th. Finally, Guggenheim upgraded Amneal Pharmaceuticals from a sell rating to a neutral rating in a report on Tuesday, May 12th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of Hold and an average target price of $4.67.

Shares of Amneal Pharmaceuticals stock opened at $4.91 on Friday. Amneal Pharmaceuticals has a one year low of $2.27 and a one year high of $5.79. The company has a debt-to-equity ratio of 7.26, a current ratio of 1.84 and a quick ratio of 1.38. The stock’s 50-day moving average is $4.73 and its 200 day moving average is $4.22. The firm has a market cap of $1.43 billion, a price-to-earnings ratio of -3.05, a PEG ratio of 0.35 and a beta of 1.52.

Amneal Pharmaceuticals (NYSE:AMRX) last announced its earnings results on Monday, May 11th. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.09 by $0.11. Amneal Pharmaceuticals had a positive return on equity of 22.05% and a negative net margin of 11.85%. The company had revenue of $498.50 million for the quarter, compared to analyst estimates of $446.12 million. During the same quarter in the prior year, the company earned $0.14 EPS. The firm’s revenue for the quarter was up 12.0% compared to the same quarter last year. On average, sell-side analysts expect that Amneal Pharmaceuticals will post 0.53 EPS for the current fiscal year.

In related news, Director Jeffrey P. George bought 23,810 shares of the company’s stock in a transaction dated Friday, May 15th. The shares were bought at an average price of $4.16 per share, for a total transaction of $99,049.60. Following the completion of the acquisition, the director now directly owns 23,810 shares of the company’s stock, valued at $99,049.60. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director John Kiely purchased 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 19th. The shares were acquired at an average cost of $4.53 per share, with a total value of $45,300.00. 26.32% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently modified their holdings of AMRX. Norges Bank purchased a new stake in shares of Amneal Pharmaceuticals during the fourth quarter valued at approximately $5,131,000. Federated Hermes Inc. increased its position in shares of Amneal Pharmaceuticals by 251.4% during the first quarter. Federated Hermes Inc. now owns 1,464,659 shares of the company’s stock valued at $5,097,000 after acquiring an additional 1,047,868 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Amneal Pharmaceuticals by 147.1% during the fourth quarter. Bank of New York Mellon Corp now owns 1,322,416 shares of the company’s stock valued at $6,374,000 after acquiring an additional 787,166 shares during the last quarter. Marshall Wace LLP increased its position in shares of Amneal Pharmaceuticals by 5,720.5% during the fourth quarter. Marshall Wace LLP now owns 609,935 shares of the company’s stock valued at $2,940,000 after acquiring an additional 599,456 shares during the last quarter. Finally, Bank of America Corp DE increased its position in shares of Amneal Pharmaceuticals by 205.8% during the fourth quarter. Bank of America Corp DE now owns 721,720 shares of the company’s stock valued at $3,478,000 after acquiring an additional 485,692 shares during the last quarter. 32.45% of the stock is owned by institutional investors.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

Featured Article: Moving Average Convergence Divergence (MACD)

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.